NCT02617745 (GLIOPLAK) is a Phase 2 clinical trial of Platelet level determination in Glioblastoma, sponsored by Centre Henri Becquerel.

Who is sponsoring NCT02617745?

NCT02617745 is sponsored by Centre Henri Becquerel.

What drugs are being tested in NCT02617745?

Interventions in NCT02617745: Platelet level determination.

What condition does NCT02617745 study?

NCT02617745 studies Glioblastoma.

Is NCT02617745 still recruiting?

NCT02617745 is currently completed. Last updated 2 January 2026.

Last reviewed 2026-01-02 · How we verify

NCT02617745: GLIOPLAK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid

Completed Phase 2 Last updated 2 January 2026

What this trial tests

Phase 2 trial testing Platelet level determination in Glioblastoma in 244 participants. Completed in 5 June 2024.

Timeline

30 November 2015

Primary endpoint
28 November 2022

5 June 2024

Quick facts

Lead sponsor	Centre Henri Becquerel
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	244
Start date	30 November 2015
Primary completion	28 November 2022
Estimated completion	5 June 2024
Sites	1 location across France

Drugs / interventions tested

Platelet level determination

Conditions studied

Glioblastoma — all drugs for Glioblastoma →

Sponsor

Centre Henri Becquerel — full company profile →

Who can join

18 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of GLIOPLAK is to evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. The studied parameter is the variation in platelet count during the radio-chemotherapy phase. The main objective is to identify early in Stupp protocol a group of patients having high risk to undergo thrombocytopenia in maintenance phase of temozolomide. With this result an algorithm of platelet monitoring for patients treated with Stupp protocol wil be proposed.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma.
Fontanilles M, Marguet F, Beaussire L, Magne N, et al · · 2020 · cited 41× · PMID 33148330 · DOI 10.1186/s40478-020-01057-7
Metabolic remodeling in glioblastoma: a longitudinal multi-omics study.
Fontanilles M, Heisbourg JD, Daban A, Di Fiore F, et al · · 2024 · cited 12× · PMID 39394177 · DOI 10.1186/s40478-024-01861-5
Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
Fontanilles M, Marguet F, Ruminy P, Basset C, et al · · 2020 · cited 11× · PMID 32303258 · DOI 10.1186/s40478-020-00917-6
Impact of EGFR<sup>A289T/V</sup> mutation on relapse pattern in glioblastoma.
Noeuveglise A, Sarafan-Vasseur N, Beaussire L, Marguet F, et al · · 2023 · cited 7× · PMID 36566697 · DOI 10.1016/j.esmoop.2022.100740
Prognostic value of circulating short-length DNA fragments in unresected glioblastoma patients.
Daban A, Beaussire-Trouvay L, Lévêque É, Alexandru C, et al · · 2024 · cited 2× · PMID 38340682 · DOI 10.1016/j.tranon.2024.101897
Machine Learning-Driven Metabolomic Biomarker Discovery in Glioblastoma: Advances, Challenges, and Future Directions.
Shih T, Hodeify R, Kaur J, Alnuaimi M, et al · · 2026 · PMID 42123428 · DOI 10.3390/ijms27093842

Verify or expand the search:

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Centre Henri Becquerel trials

Trials by the same sponsor.

NCT07499765 — Benefits of Formalized Care Support Program Following Acute Leukemia Diagnosis · NA · not yet recruiting
NCT07259915 — Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck · NA · not yet recruiting
NCT07285564 — Performance of 18F-FDG Micro-PET-CT in the Assessment of Surgical Margins in Head and Neck Cancer · NA · recruiting
NCT07190755 — Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinom · NA · recruiting
NCT07029100 — Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02617745 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Henri Becquerel
Last refreshed: 2 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02617745.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing